Enliven Therapeutics (ELVN) Shares Outstanding (2019 - 2026)

Enliven Therapeutics (ELVN) has 7 years of Shares Outstanding (Entity) data on file, last reported at $60.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Entity) rose 24.17% year-over-year to $60.9 million; the trailing twelve-month figure through Mar 2026 stood at $60.9 million (up 24.17% YoY), and the FY2025 full-year result was $59.4 million, up 21.46% from the prior year.
• Shares Outstanding (Entity) advanced to $60.9 million in Q1 2026, from $59.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $60.9 million in Q1 2026 to a low of $6.6 million in Q1 2022.
• A 5-year average of $38.0 million and a median of $46.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) climbed 0.04% in 2022 and soared 528.32% in 2023, its largest moves.
• Tracing ELVN's Shares Outstanding (Entity) over 5 years: stood at $6.6 million in 2022, then soared by 528.32% to $41.3 million in 2023, then grew by 18.51% to $48.9 million in 2024, then increased by 21.46% to $59.4 million in 2025, then rose by 2.44% to $60.9 million in 2026.
• Business Quant data shows ELVN's Shares Outstanding (Entity) at $60.9 million in Q1 2026, $59.4 million in Q4 2025, and $59.3 million in Q3 2025.